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• Multiple myeloma (MM) is a cancer of plasma cells,
which is a white blood cell that normally produces
antibodies.
• Treatment in patients younger than 65 years old is
typically high dose chemotherapy, usually with
bortezomib-based regimens or lenalidomide-
dexamethasone, followed by a stem cell transplant.
• For patients with relapsed myeloma, carfilzomib is
usually the treatment of choice.
• Carfilzomib is a highly selective, irreversible
proteasome inhibitor that binds to the 20S
proteasome. Several studies have illustrated that
carfilzomib has been associated with cardiovascular
adverse events (CVAE).
• Current literature on the role and effect of
bortezomib on cardiotoxicity is contradictory.
• Past studies have shown benefits of using
carfilzomib in MM patients, leading to improved
response rates and overall survival.
• There is scarce research on the risk factors
associated with the development of cardiotoxicity
with carfilzomib.
Objective
To determine the incidence of cardiovascular
adverse events (CVAE) associated with
carfilzomib and bortezomib utilization and to
assess risk factors for carfilzomib related
cardiotoxicity.
• Study design: Retrospective study of adult
multiple myeloma patients from 2014-2020, treated
at Cooper University Hospital.
• Main Outcome and Exposure: Cardiotoxicity and
carfilzomib/bortezomib based medical therapy.
• Data extraction: Patients will be identified based
on their diagnosis from the Cooper tumor registry.
Patients who show a history of therapy with the
study intervention will be used in our study. Further
data will be extracted using EPIC.
• Analysis: Patient factors will be analyzed using the
Wilcoxon rank-sum test for continuous variables
and chi-square test for categorical variables.
• Subsequently multivariate analysis will be
performed to identify risk factors for developing
post intervention cardiac adverse events.
• Cumulative incidence of Cardiac adverse events will
be compared between bortezomib and carfilzomib
using the log-rank test.
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Significance
More research needs to be done in this area to
further understand the best candidates for the
Carfilzomib and Bortezomib and if there are any
modifiable factors to decrease the risk of
cardiotoxicity in these patients.
Fig 1. The cellular effects of Carfilzomib (Landgren et al., 2019)
Limitation 
• Data extraction may be prone to human error due
to variations in coding.
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Hypothesis
Patients with baseline systolic and diastolic
dysfunction have higher incidence of
cardiotoxicity with carfilzomib use compared to
patients without prior cardiovascular conditions.
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